MEGACE ES Rx
Generic Name and Formulations:
Megestrol acetate 125mg/mL; oral susp; lemon-lime flavor.
Par Pharmaceutical, Inc.
Indications for MEGACE ES:
Anorexia, cachexia, or unexplained significant weight loss in patients diagnosed with AIDS.
Limitations Of use:
Should only be instituted after treatable causes of weight loss are sought and addressed. Not for prophylactic use to avoid weight loss.
625mg/5mL per day.
Known or suspected pregnancy (Cat.X).
Do not substitute with other megestrol suspensions (not interchangeable). History of thromboembolic disease. Monitor for signs/symptoms of adrenal insufficiency; consider empiric therapy if occurs. Diabetes. Renal impairment. Elderly. Avoid in women of childbearing potential. Nursing mothers: not recommended.
May increase insulin requirements. Decreases indinavir levels.
Nausea, diarrhea, impotence, rash, flatulence, hypertension, asthenia; rare: adrenal insufficiency, breakthrough bleeding.
Concentrated susp (125mg/mL)—5oz
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Differences in Efficacy and Tolerability of ADHD Medications Across Age Groups
- Rapid Cycling Bipolar Disorder Associated With ADHD and Female Gender
- Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia
- Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
- Symptom Trajectories Vary According to Language Development in Autism
- Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations
- Selective Serotonin Reuptake Inhibitors May Increase Risk for Suboptimal Fetal Growth
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Prenatal Insecticide Exposure in Mother May Be Linked to Risk for Autism in Children